Engflag

Speciafoldine

Quick links to important sections

Speciafoldine

Speciafoldine_EN

Method of action: Antianemic, Compensating Deficiency Of Folic Acid, Hematopoietic, Metabolic, Nutritive Agent

Treatment option: Beriberi, Alcoholism, Anemia, Pregnancy, Malabsorption Syndrome, Sprue, Tropical Sprue, Folic Acid

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Speciafoldine

Speciafoldine is a highly defined pharmaceutical product providing Folic Acid, an essential nutrient vital for cell maintenance and blood health.

Quick Facts: Speciafoldine Identity

Property Description
Active Ingredient Folic Acid (pteroylglutamic acid)
Pharmacological Class B complex vitamin, hematinic agent
Primary Forms Tablet, injectable solution
General Purpose Supports DNA synthesis and red blood cell production
Origin Synthetic form of Vitamin B9

What Type of Medicine is Speciafoldine? (Identity & Classification)

Speciafoldine is a pharmaceutical preparation whose sole active ingredient is Folic Acid, categorized under the high-level pharmacological class of B complex vitamins and functionally as a hematinic agent. This medicine provides an essential nutrient required for critical biological processes. The classification of Folic Acid as an essential nutrient is clinically recognized worldwide for its indispensable role in public health initiatives, often relating to nutritional support.

The preparation is a single-ingredient product, typically positioned for broad use in adults and pregnant women, and is commonly supplied as a tablet for oral administration and an injectable solution for parenteral administration.

Is Speciafoldine Natural or Synthetic? (Composition & Origin)

The Folic Acid present in Speciafoldine is the synthetic form of Vitamin B9, which is chemically stable and efficiently absorbed. This makes it distinct from folate, which is the naturally occurring equivalent found in food sources. The product's consistent quality is associated with the high bioavailability of the synthetic pteroylglutamic acid.

Speciafoldine utilizes this stable, synthetic form to ensure the precise delivery of the substance. Its simple composition involves the active ingredient combined with a basic, non-active base/vehicle appropriate for the respective dosage form.

What is the General Purpose of Folic Acid? (High-Level Benefit)

The general purpose of administering Speciafoldine is to support vital cellular health, specifically by acting as a cofactor to enable DNA and RNA synthesis in the body. This is crucial for all tissues undergoing rapid cell renewal.

By facilitating nucleoprotein synthesis, Folic Acid is essential for maintaining normal erythropoiesis, which is the proper production and maturation of red blood cells. Folic Acid is recognized as an essential medicine for its general role in hematopoiesis. This confirms the drug’s primary benefit lies in ensuring the body’s ability to create and maintain healthy blood components, commonly used in scenarios requiring prophylaxis or deficiency correction.

Regulatory References

  1. WHO Essential Medicines List: Folic acid

What side effects are possible with Speciafoldine?

Possible Side Effects and Safety Information

The safety profile of Speciafoldine (Folic Acid) is defined by its low general toxicity at typical therapeutic doses, alongside critical safety constraints documented in official regulatory labeling.

Adverse reactions are primarily classified by frequency and grouped into System-Organ Classes (SOCs). Gastrointestinal disturbances (such as nausea, flatulence, and anorexia) and reactions involving the Skin and Subcutaneous Tissue (including rash and pruritus) are reported, most often with a frequency classified as Rare in official documents (occurring in less than 1 in 1,000 users).

Specific effects, such as confusion, agitation, and sleep disturbances, have been associated with the chronic administration of very high doses of the active ingredient over prolonged periods.

Critical Safety Restrictions and Serious Reactions

The most significant safety constraint is the risk of Obscuring Pernicious Anemia. Official regulatory documents state that the medicine must not be used to treat megaloblastic anemia of an unknown cause. Doing so may correct the blood count while allowing irreversible neurological disorders to progress due to undiagnosed Vitamin B12 deficiency.

This safety warning necessitates careful patient evaluation prior to use.

Rare, serious adverse reactions documented in regulatory sources include Anaphylactic Shock, a severe hypersensitivity reaction. Furthermore, certain formulations are contraindicated in patients with rare hereditary problems, such as specific carbohydrate intolerances, due to inactive ingredients.

Overdose and Emergency Response

Overdose of Speciafoldine (Folic Acid) is generally associated with a low risk of acute, severe toxicity, reflecting the drug's high therapeutic index. The official regulatory profile documents that overdose may result in non-specific clinical manifestations. These presentations can include gastrointestinal disturbances, such as nausea, abdominal distension, and flatulence, as well as sleep pattern disturbances and irritability. In individuals with pre-existing epilepsy, an increased frequency of seizures has been noted in the context of high intake.

Regulators mandate that any suspected overdose requires seeking immediate medical attention. This action is critical because the most significant risk associated with high-dose exposure is the potential to mask the hematological signs of an underlying Vitamin B12 deficiency. This interference may permit irreversible neurological damage to progress undetected, which is a specific concern for older adults.

For management, no specific antidote is known for Folic Acid overdose. The official management approach involves the discontinuation of Speciafoldine and the provision of symptomatic and supportive treatment. Furthermore, clinical and laboratory monitoring is required, focusing specifically on evaluating the patient's Vitamin B12 status.

Therapeutic Uses of Speciafoldine

What Speciafoldine Treats: Main Uses and Benefits

Speciafoldine, containing the essential nutrient Folic Acid, is commonly used in conditions presenting with systemic or localized discomfort. It is applied across domains where additional symptomatic support is needed, including hematology and prenatal care. The medicine is utilized to treat or prevent folic acid deficiency.

The core uses include managing megaloblastic anemia, which is a condition involving episodic or fluctuating manifestations, and is relevant for easing the symptoms associated with the risk of Neural Tube Defects (NTDs) in early pregnancy, as well as supporting patients in contexts marked by increased discomfort or tension due to high nutrient demand.

“This targeted use supports essential nutrient availability during critical phases of fetal development and helps address chronic symptoms that interfere with daily functioning.”

The medication may assist with easing symptom clusters that may become intense or disruptive, such as fatigue and weakness, and associated pallor, which are linked to symptoms related to systemic imbalance. It is also applied in addressing symptoms related to inflammatory or irritative states, relevant for managing symptoms that interfere with daily comfort, such as glossitis (sore tongue) and mouth ulcers.

Quick Fact: Relief for Anemia-Related Symptoms
Speciafoldine supports the patient during difficult episodes by easing distress related to systemic imbalance, which contributes to easing the overall symptom load of fatigue and weakness.

Regulatory References

  1. NIH MedlinePlus overview of Folic Acid

Eligibility and Restrictions for Use

Who Can and Cannot Use Speciafoldine? — Official Regulatory Information

The eligibility for Speciafoldine is defined by official regulatory documents, establishing clear patient criteria for use.

Populations for Whom Use is Prohibited or Restricted

Classification Eligibility Rule (Regulatory Basis)
Contraindicated Patients with known hypersensitivity or intolerance to Speciafoldine or any of its ingredients.
Conditional Use Must not be used as monotherapy for specific megaloblastic anemias (e.g., pernicious anemia) unless Vitamin B12 deficiency has been ruled out or adequately treated.
Restricted Use Patients with severe chronic organ impairment (e.g., GFR <25 mL/min/1.73 m^2) may require a limitation on the maximum daily dose.

Age and Physiological Status Eligibility

Speciafoldine use is established for both adults and children, with specific lower maintenance doses defined for infants and young children. For pregnant and lactating women, use is generally indicated (e.g., for deficiency states); however, during pregnancy, it is typically restricted to situations where it is clearly needed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Speciafoldine (Folic Acid) documents interaction patterns across several medicinal and substance categories, primarily affecting plasma concentrations of co-administered drugs or altering the clearance of Folic Acid itself.

Interaction scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Anticonvulsants (AEDs), Folate Antagonists, Gastrointestinal Adsorbents, Antibiotics, Oral Contraceptives.
Specific interacting medicines (if explicitly listed) Phenytoin, Phenobarbital, Primidone, Carbamazepine, Methotrexate, Pyrimethamine, Trimethoprim, Cholestyramine.
Mechanistic basis of interactions (only if stated in label) Antagonism of the anticonvulsant action (for AEDs), Antagonism of therapeutic effects (for Folate Antagonists), Reduction or delay of gastrointestinal absorption (Gastrointestinal Adsorbents).
Timing-based interaction rules (if applicable) For agents like Cholestyramine, Folic Acid must be administered at least one hour before or four to six hours after to prevent reduced absorption.
Population-specific interaction notes (if applicable) Alcohol consumption is documented to interfere with absorption and metabolism. Folic Acid alone is improper therapy for megaloblastic anemias caused by Vitamin B12 deficiency, as it may obscure the diagnosis while allowing neurological complications to progress.
Interaction-related restrictions Must not be used alone to treat megaloblastic anemia of unknown etiology.

Interaction classifications (high-level)

Category Official Regulatory Statement
Interaction severity classification (as defined in official documents) Clinically significant interaction, requiring monitoring for certain agents (e.g., Anticonvulsants, Folate Antagonists).
Regulatory basis (EMA / FDA / etc.) Consistent with FDA Prescribing Information and European monographs.
Interaction-context constraints (as defined in official documents) Requires attention to altered dose requirements for anticonvulsants and potential reduced efficacy for folate antagonists.

Resulting interaction structure

Official regulatory documents emphasize two primary constraints: Folic Acid may reduce the blood concentration and antagonize the action of Anticonvulsants like Phenytoin, and it may diminish the therapeutic effects of Folate Antagonists. Furthermore, specific agents require mandatory temporal separation to ensure proper absorption. The profile mandates a procedural caution: Folic Acid must not be used to treat megaloblastic anemia of unknown cause due to the risk of masking neurological decline.

Mechanism of Action

How Speciafoldine Works: Pharmacodynamics

Speciafoldine's action is defined by its interaction with the Sphingosine-1-Phosphate Receptor 1 (S1P1), a protein expressed on circulating immune cells, including T and B lymphocytes. The drug acts as a functional antagonist by binding to S1P1 and promoting its rapid downregulation through internalization and degradation. This molecular event prevents lymphocytes from sensing the S1P gradient, which is required for their mobility.

By functionally disabling the S1P1 receptor, Speciafoldine inhibits the egress of T and B cells from secondary lymphoid organs, such as the lymph nodes and spleen, resulting in their sequestration. The resulting physiological consequence is a sustained and reversible lymphopenia—a decrease in the concentration of these circulating lymphocytes in the peripheral blood. This mechanism reduces the cellular input into the systemic immune process by limiting the availability of lymphocytes to accumulate in peripheral tissues.

Dosage and Administration Information

How to Use Speciafoldine

Speciafoldine, containing Folic Acid, is administered according to standardized principles for both therapeutic and prophylactic use. The primary route of administration is oral, utilizing available tablet strengths that commonly range from 0.4 mg to 5 mg. The tablets may be taken with or without food, providing flexible daily scheduling.

For individuals with impaired intestinal absorption or in severe cases, the medicine may be given by a parenteral route, including intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection. When administering the injectable solution, a direct intravenous injection must be administered slowly, typically over a period of at least one minute.

Standard adult therapeutic dosing for deficiency typically involves 0.4 mg to 1 mg once daily. In cases of severe malabsorption, the required daily quantity may be higher, potentially reaching up to 15 mg. Prophylactic use, such as for the prevention of Neural Tube Defects, generally employs a 0.4 mg dose once daily, starting before conception and continuing through the first trimester.

The initial therapeutic course continues until clinical and blood parameters have normalized, often requiring approximately four months of continuous daily use. Subsequent lower maintenance doses are established after the initial course, with specific ranges designated for pediatric patients based on age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Speciafoldine (Folic Acid)

Evidence for Preventing Neural Tube Defects (NTDs)

Speciafoldine, which provides Folic Acid, was studied for its role in preventing conditions known as Neural Tube Defects (NTDs). Research has primarily involved Randomized Controlled Trials (RCTs) focusing on preventing the recurrence of NTDs in high-risk women. In addition, large-scale observational studies and systematic reviews have been applied in studies examining the evidence for primary prevention in the general population of women capable of conception.

Outcomes studied included the incidence of NTD-affected pregnancies, along with biomarkers such as the levels of Folic Acid in red blood cells and serum. Findings indicate a consistent pattern across multiple research efforts regarding the incidence of NTD-affected pregnancies in the groups studied who received Folic Acid during the crucial periconceptional period.

Evidence for Managing Folic Acid Deficiency-Related Anemia

Speciafoldine was evaluated in research settings to manage megaloblastic anemia that is specifically caused by a Folic Acid deficiency. Studies have included Randomized Controlled Trials (RCTs) and comprehensive systematic reviews that focus on correcting the underlying deficiency. Research examined the effects of Speciafoldine administration on correcting key hematological parameters.

Findings describe patterns observed in the studies where the administration of Speciafoldine was associated with reported changes in key hematological parameters (e.g., hemoglobin) that were tracked in patients with confirmed deficiency. Studies also monitored associated symptom clusters, such as general weakness and fatigue, alongside changes in blood parameters.

What is Still Uncertain About Speciafoldine Research

Despite being an essential, widely studied nutrient, certain scientific questions regarding Speciafoldine remain uncertain and require continued research. For instance, research protocols regarding deficiency treatment require the exclusion of concurrent Vitamin B12 deficiency; this must be considered when evaluating the evidence. Data concerning the optimal maintenance period after the acute deficiency is corrected, particularly in chronic high-demand states, are still emerging. Therefore, long-term effects are not fully established outside of population surveillance contexts.

Key Studies & References

  1. Folate Deficiency - Nutritional Disorders (Merck Manual Professional Edition on Anemia Management)

Frequently Asked Questions (FAQ)

Common questions about Speciafoldine (FAQ)

Q: What should I do if I take too much Speciafoldine (overdose)?

Official regulatory documents indicate that Folic Acid has low toxicity at typical doses. However, chronic or acute administration of very high doses has been associated with effects such as confusion and sleep disturbances. Official documents generally recommend that if too much medicine is taken, healthcare professionals should be consulted for appropriate medical advice.

Q: Is Speciafoldine the same as the folate found in foods?

No, they are not exactly the same. According to official product information, Speciafoldine contains Folic Acid, which is the synthetic form of the vitamin (pteroylglutamic acid). Folate is the term used for the naturally occurring equivalent found in various food sources.

Q: How long does it take for Speciafoldine to start working for anemia?

Studies and official information indicate that Speciafoldine starts working by providing the essential nutrient needed for DNA synthesis and red blood cell production. The body begins the process of blood cell production following administration; however, the initial therapeutic course required to help normalize blood parameters often involves continuous daily use for a period up to four months.

Q: What if I take Speciafoldine with alcohol?

Official regulatory documents indicate that alcohol consumption may interfere with the absorption and metabolism of Folic Acid. This potential interaction may be a consideration for patients using the medicine, as detailed in the official product information.

Q: What are the storage instructions for Speciafoldine tablets and injections?

Official product information specifies that both forms should be stored at controlled room temperature, typically between 20 C and 25 C, and protected from moisture and light. Regulatory guidelines emphasize that the injectable solution must not be frozen. Disposal of any unused product, including injectable solution remnants, should follow local regulatory requirements for pharmaceutical waste.

How should Speciafoldine be stored and disposed of?

The storage and disposal of Speciafoldine (Folic Acid) are defined by strict regulatory guidelines to maintain potency and ensure safety.

Storage Domain Official Regulatory Requirement
Temperature Store at controlled room temperature (e.g., 20 C to 25 C).
Protection Keep the product in the original, tightly closed container and protect from moisture and light.
Prohibited The injectable solution must not be frozen and oral forms must not exceed 30 C (86 F).
Child Safety Keep out of the sight and reach of children.

For stability, any unused portion of the injectable solution must be discarded immediately after initial use. Unused or expired Speciafoldine must not be discarded via wastewater or household waste; disposal must follow local regulatory requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagFrance

Equivalent of Speciafoldine found in:

A-Z Index: